These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1056 related articles for article (PubMed ID: 23587330)

  • 1. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
    Ann J; Samant M; Rheaume C; Dumas C; Beaulieu E; Morasse A; Mallett C; Hamelin ME; Papadopoulou B; Boivin G
    Vaccine; 2014 Sep; 32(43):5730-9. PubMed ID: 25173481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza.
    Heath MD; Swan NJ; Marriott AC; Silman NJ; Hallis B; Prevosto C; Gooch KE; Skinner MA
    BMC Infect Dis; 2017 Mar; 17(1):232. PubMed ID: 28347293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.
    Sun X; Belser JA; Pulit-Penaloza JA; Creager HM; Guo Z; Jefferson SN; Liu F; York IA; Stevens J; Maines TR; Jernigan DB; Katz JM; Levine MZ; Tumpey TM
    Virology; 2017 Aug; 508():164-169. PubMed ID: 28554058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.
    Maltais AK; Stittelaar KJ; Veldhuis Kroeze EJ; van Amerongen G; Dijkshoorn ML; Krestin GP; Hinkula J; Arwidsson H; Lindberg A; Osterhaus AD
    Vaccine; 2014 May; 32(26):3307-15. PubMed ID: 24690149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.
    Bragstad K; Martel CJ; Thomsen JS; Jensen KL; Nielsen LP; Aasted B; Fomsgaard A
    Influenza Other Respir Viruses; 2011 Jan; 5(1):13-23. PubMed ID: 21138536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.
    Rockman S; Brown LE; Barr IG; Gilbertson B; Lowther S; Kachurin A; Kachurina O; Klippel J; Bodle J; Pearse M; Middleton D
    J Virol; 2013 Mar; 87(6):3053-61. PubMed ID: 23283953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models.
    Park SJ; Kim EH; Pascua PNQ; Kwon HI; Lim GJ; Decano A; Kim SM; Song MK; Shin EC; Choi YK
    J Gen Virol; 2014 Apr; 95(Pt 4):793-798. PubMed ID: 24421115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.
    Girard MP; Katz JM; Pervikov Y; Hombach J; Tam JS
    Vaccine; 2011 Oct; 29(44):7579-86. PubMed ID: 21856358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.
    Pushko P; Pearce MB; Ahmad A; Tretyakova I; Smith G; Belser JA; Tumpey TM
    Vaccine; 2011 Aug; 29(35):5911-8. PubMed ID: 21723354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V; De Serres G; Hamelin ME; Boivin G; Ouakki M; Boulianne N; Sauvageau C; Dionne M; Gilca R; Skowronski D
    Vaccine; 2011 Dec; 30(1):35-41. PubMed ID: 22063386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge.
    Major D; Chichester JA; Pathirana RD; Guilfoyle K; Shoji Y; Guzman CA; Yusibov V; Cox RJ
    Hum Vaccin Immunother; 2015; 11(5):1235-43. PubMed ID: 25714901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets.
    Baras B; de Waal L; Stittelaar KJ; Jacob V; Giannini S; Kroeze EJ; van den Brand JM; van Amerongen G; Simon JH; Hanon E; Mossman SP; Osterhaus AD
    Vaccine; 2011 Mar; 29(11):2120-6. PubMed ID: 21238573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
    Fiore AE; Uyeki TM; Broder K; Finelli L; Euler GL; Singleton JA; Iskander JK; Wortley PM; Shay DK; Bresee JS; Cox NJ;
    MMWR Recomm Rep; 2010 Aug; 59(RR-8):1-62. PubMed ID: 20689501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant.
    Stavaru C; Onu A; Lupulescu E; Tucureanu C; Rasid O; Vlase E; Coman C; Caras I; Ghiorghisor A; Berbecila L; Tofan V; Bowen RA; Marlenee N; Hartwig A; Bielefeldt-Ohmann H; Baldwin SL; Van Hoeven N; Vedvick TS; Huynh C; O'Hara MK; Noah DL; Fox CB
    Hum Vaccin Immunother; 2016 Apr; 12(4):1009-26. PubMed ID: 26618392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.